Gilead Sciences, Inc (NASDAQ: GILD) is 24.22% higher on its value in year-to-date trading and has touched a low of $62.07 and a high of $117.16 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The GILD stock was last observed hovering at around $115.99 in the last trading session, with the day’s loss setting it -1.25%.
Currently trading at $114.74, the stock is 8.26% and 16.97% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 11.98 million and changing -1.08% at the moment leaves the stock 36.87% off its SMA200. GILD registered 59.14% gain for a year compared to 6-month gain of 44.42%.
The stock witnessed a 18.05% loss in the last 1 month and extending the period to 3 months gives it a 24.16%, and is 2.88% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.58% over the week and 2.33% over the month.
Gilead Sciences, Inc (GILD) has around 17600 employees, a market worth around $142.89B and $28.73B in sales. Current P/E ratio is 312.56 and Fwd P/E is 13.64. Profit margin for the company is 1.67%. Distance from 52-week low is 84.86% and -2.07% from its 52-week high. The company has generated returns on investments over the last 12 months (1.07%).
with sales reaching $6.76B over the same period.The EPS is expected to grow by 71.83% this year, but quarterly earnings will post -0.38% year-over-year. Quarterly sales are estimated to grow 1.18% in year-over-year returns.
Gilead Sciences, Inc (GILD) Top Institutional Holders
The shares outstanding are 1.25B, and float is at 1.24B with Short Float at 1.70%.
The top institutional shareholder in the company is BLACKROCK INC. with over 120.63 million shares valued at $8.28 billion. The investor’s holdings represent 9.6738% of the GILD Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 115.26 million shares valued at $$7.91 billion to account for 9.2431 of the shares outstanding. The other top investors are CAPITAL WORLD INVESTORS which holds 76.25 million shares representing 6.1147% and valued at over $5.23 billion, while CAPITAL RESEARCH GLOBAL INVESTORS holds 4.8458 of the shares totaling 60.43 million with a market value of $4.15 billion.
Gilead Sciences, Inc (GILD) Insider Activity
A total of 0 insider transactions have happened at Gilead Sciences, Inc (GILD) in the last six months, with sales accounting for 0 and purchases happening 0 times.
Gilead Sciences, Inc disclosed in a document filed with the SEC on Feb 18 ’25 that GILEAD SCIENCES, INC. (10% Owner) bought a total of 1,363,636 shares of the company’s common stock. The trade occurred on Feb 18 ’25 and was made at $11.00 per share for $15.0 million. Following the transaction, the insider now directly holds 31.42 million shares of the GILD stock.
Still, SEC filings show that on Feb 18 ’25, Dickinson Andrew D (Chief Financial Officer) disposed off 2,500 shares at an average price of $104.09 for $0.26 million. The insider now directly holds 169,061 shares of Gilead Sciences, Inc (GILD).
Gilead Sciences, Inc (GILD): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 3.82% up over the past 12 months. Pfizer Inc. (PFE) that is -5.30% lower over the same period.
